Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06447740

Fractional Flow Reserve-guided Stenting Versus Medical Therapy in Atherosclerosis Renal Artery Stenosis

Although randomized trials have demonstrated there is no benefit of renal-artery stenting in addition to medical therapy for patients with atherosclerosis renal artery stenosis, many patients indeed gained benefit in daily practices after stenting, such as reduction in blood pressure and recovery in renal functions. One important gap is that there is no universal standard to determine whether to stent in these patients. Fraction Flow Reserve (FFR) has been studied for many year in chronic coronary heart disease and FFR-guided revascularization strategy is known to be better than both angiography-guided revascularization and medication alone. Based on the primary finding of FAIR-pilot study (NCT05732077), FFR-guided renal artery stenting is practical.

The overall purpose of the FAIR trial is to compare the clinical outcomes and safety of FFR-guided stenting plus optimal medical treatment (OMT) versus OMT alone in patients with renal-vascular hypertensive patients.

With the 'all comers' design, participants met the inclusive/exclusive criteria will be enrolled, and hyperemic FFR induced by dopamine will be measured in all participants. If FFR is ≥0.80, patients will be treated with OMT alone and follow up. If FFR is <0.80, participants will be randomized to stenting in the renal artery plus OMT or OMT alone on a 1:1 ratio. The blood pressure and anti-hypertensive medications will be compared before and 3 months after the procedure based on ambulatory blood pressure monitoring, all participants will be followed up for 1 year.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Peking University First Hospital

Beijing, Beijing Municipality, 100034, China

Location status: Recruiting

Location contact

Jianping Li, MD

PRINCIPAL_INVESTIGATOR

Yuxi Li, MD

CONTACT

[email protected]

00861083572283

Yuxi Li, MD

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • With recorded hypertension, AND the blood pressure is not controlled (daytime mean SBP ≥135 mmHg and/or DBP ≥85 mmHg based on ABPM) on 2 or more classes of anti-hypertensive drugs;
  • Evidence of renal artery stenosis and undergoing renal artery angiography;
  • Able to follow the study protocol and provide informed consent;
  • Renal artery angiography shows at least 1 main artery with stenosis of 50%-90%, AND the diameter is ≥ 4.0mm.

Exclusion criteria

  • SBP ≥200mmHg and/or DBP ≥120mmHg at the day or randomization;
  • Fibromuscular dysplasia or other non-atherosclerotic renal artery stenosis;
  • Pregnancy or unknown pregnancy status in female of childbearing potential;
  • Participation in any drug or device trial during the study period;
  • Any stroke/TIA, OR with ≥70% stenosis of carotid artery;
  • Any major surgery, myocardial infarction or interventional therapy 30 days prior to study entry;
  • LVEF <30%;
  • Comorbidity condition causing life expectancy ≤1 year;
  • Allergy to contrast or any of the following: aspirin, clopidogrel;
  • Previous kidney transplant;
  • Previous renal artery bypass surgery or stent intervention;
  • Kidney size less than 8 cm measured by ultrasound;
  • Local lab serum Cr >3.0 mg/dl (265.2μmol/l) on the day of randomization;
  • Reference vessel size <4 mm or >8 mm.

Treatment and study plan

Dopamine

Drug

A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status

Fractional Flow Reserve, Renal

Diagnostic Test

Renal FFR will be measured based on SOP

Renal artery stenting

Device

Renal artery stenting will be implanted based on the protocol

Primary outcomes

  1. Change in daytime mean systolic blood pressure as measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)

    Time frame: From baseline to 3 months post-procedure

  2. Change in the composite index of antihypertensive drugs

    Time frame: From baseline to 3 months post-procedure

    Change in the composite index of antihypertensive drugs. Drug Composite Index = Weight (number of classes of antihypertensive drugs) × (sum of doses)

Secondary outcomes

  1. Change in systolic blood pressure as measured by 24-hour ABPM

    Time frame: From baseline to 3 months post-procedure

  2. Change in diastolic blood pressure as measured by 24-hour ABPM

    Time frame: From baseline to 3 months post-procedure

  3. Change in home blood pressure

    Time frame: From baseline to 3 months post-procedure

  4. Change in office blood pressure

    Time frame: From baseline to 3 months post-procedure

  5. Change in the composite index of antihypertensive drugs to reach target blood pressure

    Time frame: From baseline to 1 year post-procedure

    Change in the composite index of antihypertensive drugs to reach target blood pressure. Drug Composite Index = Weight (number of classes of antihypertensive drugs) × (sum of doses)

  6. Change in ABPM

    Time frame: From baseline to 6 months, 1 year post-procedure

  7. All-cause death

    Time frame: From baseline to 1 year post-procedure

  8. Cardiac death

    Time frame: From baseline to 1 year post-procedure

  9. Acute myocardial infarction incidence

    Time frame: From baseline to 1 year post-procedure

    Based on universal definition of acute myocardial infarction

  10. Non-fatal stroke incidence

    Time frame: From baseline to 1 year post-procedure

    Based on medical records under outcome committee's judge

  11. Rehospitalization due to heart failure incidence

    Time frame: From baseline to 1 year post-procedure

    Based on medical records under outcome committee's judge

  12. Change in serum creatinine or dialysis

    Time frame: From baseline to 1 year post-procedure

Study contacts

Contact information is provided by the study sponsor or research team.

Yuxi Li, MD

CONTACT

[email protected]

00861083572283

Sponsors and collaborators

Lead sponsor

Peking University First Hospital

Other

Registry information

Official study title

Fractional Flow Reserve-guided Percutaneous Renal Artery Stenting Plus Optimal Medical Therapy Versus Optimal Medical Therapy Alone In Atherosclerosis Renal-vascular Hypertension Patients: a Multicenter Randomized Trial

Acronym: FAIR

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Jun 7, 2024
Registry last updated
Aug 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.